Montreux Equity Partners V, L.P. insider trades: EPIRUS Biopharmaceuticals (EPRS) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Montreux Equity Partners V, L.P. reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 6, 2015 | EPRS | ↓ Sell | 167,316 | $5.00 | $836K | Direct | Feb 9, 2015 (3d) |
| Feb 4, 2015 | EPRS | ↓ Sell | 52,684 | $4.98 | $263K | Direct | Feb 5, 2015 (1d) |
| Jan 26, 2015 | EPRS | ↓ Sell | 38,516 | $6.47 | $249K | Direct | Jan 28, 2015 (2d) |
| Jan 23, 2015 | EPRS | ↓ Sell | 22,530 | $6.29 | $142K | Direct | Jan 26, 2015 (3d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Montreux Equity Partners V, L.P.'s insider trades
Montreux Equity Partners V, L.P. is a 10% owner of EPIRUS Biopharmaceuticals (EPRS). Since Jan 23, 2015, it has reported no open-market purchases and 4 sales worth $1.5M on SEC Form 4. There have been no open-market trades in the last 12 months.
Its filings also include other transactions (1 filing), conversions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every EPRS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.